Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.

[1]  A. Edefonti,et al.  Rituximab in children with resistant idiopathic nephrotic syndrome. , 2012, Journal of the American Society of Nephrology : JASN.

[2]  L. Weber,et al.  Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  A. Edefonti,et al.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[4]  M. Rastaldi,et al.  Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.

[5]  D. Maloney,et al.  Rituximab resistance. , 2011, Best practice & research. Clinical haematology.

[6]  A. Sinha,et al.  Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[7]  W. Oyen,et al.  Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[8]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[9]  G. Deschênes,et al.  Fatal pulmonary fibrosis after rituximab administration , 2009, Pediatric Nephrology.

[10]  S. Sakajiri,et al.  Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma , 2009, Clinical Cancer Research.

[11]  V. De Pinto,et al.  Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes1 , 2009, The Journal of Immunology.

[12]  Bruce D Cheson,et al.  Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. , 2008, The New England journal of medicine.

[13]  J. Groothoff,et al.  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases , 2008, Pediatric Nephrology.

[14]  M. Czuczman,et al.  Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression , 2008, Clinical Cancer Research.

[15]  R. Mertelsmann,et al.  The epitope recognized by rituximab. , 2006, Blood.

[16]  M. Pescovitz,et al.  Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. , 2006, The New England journal of medicine.

[17]  F. Dammacco,et al.  Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. , 2006, Blood.

[18]  E. Gulbins,et al.  Ceramide-enriched membrane domains. , 2005, Biochimica et biophysica acta.

[19]  M. Fujisawa,et al.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome , 2005, Pediatric Nephrology.

[20]  G. Rizzoni,et al.  Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. , 2004, Clinical therapeutics.

[21]  J. Jaffrezou,et al.  Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. , 2004, Blood.

[22]  A. Edefonti,et al.  A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome , 1993, Pediatric Nephrology.

[23]  H. Osaka,et al.  Acute leucoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome , 1994, Pediatric Nephrology.

[24]  M. Polyak,et al.  CD20‐mediated apoptosis: signalling through lipid rafts , 2002, Immunology.

[25]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[26]  A. Ucci,et al.  Changing incidence of glomerular diseases in adults. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  M. Czuczman,et al.  Use of rituximab, the new FDA-approved antibody. , 1998, Current opinion in oncology.

[28]  D. Roos,et al.  FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .

[29]  D. Roos,et al.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.

[30]  G. Ghiggeri,et al.  Cyclosporine enhances the synthesis of selected extracellular matrix proteins by renal cells "in culture". Different cell responses and phenotype characterization. , 1994, Transplantation.

[31]  R. White,et al.  LONG-TERM OUTCOME FOR CHILDREN WITH MINIMAL-CHANGE NEPHROTIC SYNDROME , 1985, The Lancet.

[32]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[33]  B. Ramot,et al.  POSSIBLE T-LYMPHOCYTE ORIGIN OF REED-STERNBERG CELLS , 1974 .